Dr. Kris Discusses the Pemetrexed Trial Results

Mark G. Kris, MD
Published: Thursday, Jun 23, 2011

Mark G. Kris, MD, the chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the pemetrexed clinical trial results.

Dr. Kris says by continuing pemetrexed in patients who began their treatments with pemetrexed, the patients had a longer disease-free survival. Generally disease-free survival translates into life where cancer does not disrupt it. That improvement was achieved just by continuing a medicine that the patients were already on. Survival data is not out yet, and it's something that will be looked for, but regardless, the time free of cancer is clearly improved.
Mark G. Kris, MD, the chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the pemetrexed clinical trial results.

Dr. Kris says by continuing pemetrexed in patients who began their treatments with pemetrexed, the patients had a longer disease-free survival. Generally disease-free survival translates into life where cancer does not disrupt it. That improvement was achieved just by continuing a medicine that the patients were already on. Survival data is not out yet, and it's something that will be looked for, but regardless, the time free of cancer is clearly improved.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x